Extra Hospital Delivery Outside Medical Presence.
REGUL-AIpM
Evaluation of a Standardized Medical Regulation Strategy on the Reduction of Deliveries Outside Medical Presence.
1 other identifier
interventional
8,208
1 country
19
Brief Summary
The purpose of this study is to prospectively evaluate a standardized procedure of medical regulation based on a validated predictive score of eminent delivery (SPIA) in comparison with usual inhomogeneous practices. This standardized procedure impacting the process of care production (when receiving the call for regulation for unannounced delivery) would improve the quality of care of parturients while rationalizing the use of medical teams in the field.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2018
Longer than P75 for not_applicable
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 23, 2017
CompletedFirst Posted
Study publicly available on registry
December 6, 2017
CompletedStudy Start
First participant enrolled
March 14, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 14, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 14, 2021
CompletedSeptember 19, 2024
August 1, 2022
3.8 years
November 23, 2017
September 3, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of deliveries without the presence of a doctor or midwife and absence of the SMUR sent in first intention.
It will be the number of unexpected deliveries out of medical presence.
Through study completion, an average of eighteen months.
Secondary Outcomes (7)
Number of deliveries outside maternity.
Through study completion, an average of eighteen months.
Number of adapted responses.
Through study completion, an average of eighteen months.
Duration of the call collected on the regulation.
At the moment of inclusion of the patient, an average one day.
Regulatory investigator satisfaction by a standardized questionnaire.
Through study completion, an average of six months.
APGAR scores of newborn at birth and 10 minutes of delivery.
At one minute then at ten minutes.
- +2 more secondary outcomes
Study Arms (2)
Experimental group SPIA
EXPERIMENTALThe regulator will be asked to systematically use the tool Predictor score of the imminence of a childbirth (SPIA). This tool is used to evaluate the means to be sent following a call for imminent delivery outside the hospital.
Control group
NO INTERVENTIONThe classic care will be made according to the usual practices of the doctor and the center.
Interventions
The SPIA score is based on the analysis of 6 types of criteria: panic during the call, the possibility of having a telephone contact with the parturient, the urge to push and if so for how long, the rhythm of the CU, some aggravating factors (history of fast delivery or at home, maternal age between 26 and 35 years, lack of follow-up of pregnancy) and 2 minor factors (nulliparity and the taking of a tocolytic treatment). Each criteria is between 0 to 8, except for the 2 minor criteria for which 7 and 3 points are removed if they are present. This gives a score between -10 and +33, which is weighted according to the admission time estimated at the hospital (30 minutes, 1h and 2h).
Eligibility Criteria
You may qualify if:
- Pregnant woman over 33 WA
- Age ≥ 18 years
- Calling the regulation of SAMU-Center 15 for start of work
- Patient not planning to give birth at home
- Delivery not having started at the time of the first call (hair, head, buttocks or feet not visible)
- Absence of a doctor, obstetrician or midwife on the spot during the call
- French language included (Patient and / or Near)
You may not qualify if:
- Opposition of the patient after sending the information note.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hôpital NOVOlead
Study Sites (19)
Centre Hospitalier René-DUBOS
Cergy-Pontoise, Cergy-pontoise, 95303, France
Centre Hospitalier Universitaire d'Amiens
Amiens, 80080, France
Centre Hospitalier Régional Universitaire de Besançon
Besançon, 25000, France
Centre Hospitalier Universitaire Avicenne
Bobigny, 93000, France
Hôpital Pellegrin
Bordeau, 33000, France
Centre Hospitalier Henri Mondor
Créteil, 94010, France
Centre Hospitalier Universitaire de Dijon
Dijon, 21000, France
Centre Hospitalier Universitaire de Grenoble
Grenoble, 38700, France
Hôpital André Mignot
Le Chesnay, 78150, France
Centre Hospitalier Régional Universitaire de Lille
Lille, 59000, France
Groupement Hospitalier Edouard Herriot
Lyon, 69003, France
Centre Hospitalier Marc Jacquet
Melun, 77011, France
Centre Hospitalier Régional Mets-Thionville
Metz, 57000, France
Centre Hospitalier Annecy-Genevois
Metz-Tessy, 74370, France
Centre Hospitalier Universitaire de Nancy
Nancy, 54000, France
Centre Hospitalier Universitaire de Rennes
Rennes, 35033, France
Centre Hospitalier Universitaire de la Réunion
Saint-Denis, 97400, France
Centre Hospitalier de Toulon
Toulon, 83056, France
Hôpital Purpan
Toulouse, 31059, France
Study Officials
- PRINCIPAL INVESTIGATOR
Agnès RICARD-HIBON
Hôpital NOVO
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 23, 2017
First Posted
December 6, 2017
Study Start
March 14, 2018
Primary Completion
December 14, 2021
Study Completion
December 14, 2021
Last Updated
September 19, 2024
Record last verified: 2022-08
Data Sharing
- IPD Sharing
- Will not share